First National Bank of Omaha Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
First National Bank of Omaha Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
First National Bank of Omaha lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) by 26.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,371 shares of the specialty pharmaceutical company's stock after selling 5,805 shares during the quarter. First National Bank of Omaha's holdings in Supernus Pharmaceuticals were worth $529,000 at the end of the most recent reporting period.
根据奥马哈第一国民银行最近向美国证券交易委员会提交的13F文件,该行在第一季度减持了Supernus PharmPharmticals,Inc.(纳斯达克代码:SUPN-GET评级)的股票26.2%。该基金在本季度出售了5,805股后,持有这家专业制药公司的16,371股股票。在最近一次报告期结束时,奥马哈第一国民银行持有的Supernus制药公司的股份价值52.9万美元。
Several other institutional investors have also modified their holdings of SUPN. Woodline Partners LP purchased a new stake in Supernus Pharmaceuticals in the 1st quarter valued at $15,689,000. Stephens Investment Management Group LLC raised its position in Supernus Pharmaceuticals by 27.2% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,577,980 shares of the specialty pharmaceutical company's stock valued at $46,014,000 after purchasing an additional 337,902 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Supernus Pharmaceuticals by 108.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 550,081 shares of the specialty pharmaceutical company's stock valued at $17,779,000 after purchasing an additional 285,737 shares during the last quarter. GW&K Investment Management LLC raised its position in Supernus Pharmaceuticals by 13.0% in the 4th quarter. GW&K Investment Management LLC now owns 1,836,466 shares of the specialty pharmaceutical company's stock valued at $53,551,000 after purchasing an additional 210,976 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its position in Supernus Pharmaceuticals by 17.7% in the 4th quarter. Epoch Investment Partners Inc. now owns 458,155 shares of the specialty pharmaceutical company's stock valued at $13,360,000 after purchasing an additional 68,750 shares during the last quarter. Hedge funds and other institutional investors own 99.81% of the company's stock.
其他几家机构投资者也调整了对SUPN的持股。Woodline Partners LP在第一季度购买了Supernus PharmPharmticals的新股份,价值15,689,000美元。斯蒂芬斯投资管理集团LLC在第四季度将其在Supernus PharmPharmticals的头寸提高了27.2%。斯蒂芬斯投资管理集团现在拥有1,577,980股这家专业制药公司的股票,价值46,014,000美元,在上个季度又购买了337,902股。高盛股份有限公司在第一季度将其在Supernus制药的持仓提高了108.1%。高盛股份有限公司在上个季度增持了285,737股后,现在拥有550,081股这家专业制药公司的股票,价值17,779,000美元。GW&K Investment Management LLC在第四季度将其在Supernus PharmPharmticals的头寸提高了13.0%。GW&K Investment Management LLC现在拥有这家专业制药公司1,836,466股股票,价值53,551,000美元,上个季度又购买了210,976股。最后,Epoch Investment Partners Inc.在第四季度将其在Supernus PharmPharmticals的持仓提高了17.7%。在上个季度购买了68,750股股票后,年代投资伙伴公司现在拥有458,155股这家专业制药公司的股票,价值13,360,000美元。对冲基金和其他机构投资者持有该公司99.81%的股票。
Analysts Set New Price Targets
分析师设定新的价格目标
Several research firms recently commented on SUPN. StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, September 2nd. Piper Sandler upped their price objective on shares of Supernus Pharmaceuticals to $38.00 in a research report on Tuesday, September 6th.
几家研究公司最近对SUPN发表了评论。在9月2日(周五)的一份研究报告中,StockNews.com将Supernus PharmPharmticals的股票评级从“买入”上调至“强力买入”。派珀·桑德勒在9月6日星期二的一份研究报告中将Supernus制药公司的股票目标价上调至38.00美元。
Insider Transactions at Supernus Pharmaceuticals
Supernus制药公司的内幕交易
Supernus Pharmaceuticals Stock Performance
Supernus制药类股表现
Shares of Supernus Pharmaceuticals stock opened at $34.90 on Friday. The company has a market cap of $1.87 billion, a P/E ratio of 34.55 and a beta of 1.01. Supernus Pharmaceuticals, Inc. has a one year low of $24.95 and a one year high of $36.08. The firm has a fifty day moving average of $32.64 and a two-hundred day moving average of $30.49.
Supernus制药公司的股票周五开盘报34.90美元。该公司市值18.7亿美元,市盈率为34.55倍,贝塔系数为1.01。Supernus PharmPharmticals,Inc.的一年低点为24.95美元,一年高位为36.08美元。该公司的50日移动均线切入位为32.64美元,200日移动均线切入位为30.49美元。
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by ($0.15). Supernus Pharmaceuticals had a return on equity of 6.98% and a net margin of 9.12%. The company had revenue of $170.10 million for the quarter, compared to analyst estimates of $164.23 million. During the same period last year, the company earned $0.43 earnings per share. The business's revenue for the quarter was up 20.4% compared to the same quarter last year. As a group, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 1.51 earnings per share for the current year.
超威制药(纳斯达克代码:SUPN-GET Rating)最近一次公布季度收益是在8月4日星期四。这家专业制药公司公布本季度每股收益为0.14美元,低于分析师普遍预期的0.29美元(0.15美元)。Supernus制药公司的股本回报率为6.98%,净利润率为9.12%。该公司本季度营收为1.701亿美元,而分析师预期为1.6423亿美元。去年同期,该公司每股收益为0.43美元。与去年同期相比,该业务本季度的收入增长了20.4%。作为一个整体,股票分析师预计Supernus PharmPharmticals,Inc.本年度每股收益将达到1.51美元。
About Supernus Pharmaceuticals
关于Supernus制药公司
(Get Rating)
(获取评级)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.
Supernus制药公司是一家生物制药公司,在美国专注于治疗中枢神经系统(CNS)疾病的产品的开发和商业化。它的商业产品是Trokendi XR,这是一种用于治疗癫痫和预防偏头痛的托吡酯缓释剂;奥克泰拉XR是一种缓释型奥卡西平,用于单一疗法治疗6至17岁的成人和儿童部分发作癫痫。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Supernus Pharmaceuticals (SUPN)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- 免费获取StockNews.com关于Supernus制药公司的研究报告(SUPN)
- 第四季度值得考虑的3家银行
- 股市:红海中的三座强国
- 有什么办法可以治愈Teladoc股票的问题吗?
- 没有人告诉这三只股票这是下跌的一周
- MarketBeat:回顾一周9/12-9/16
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Supernus PharmPharmticals Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Supernus制药公司和相关公司的最新新闻和分析师评级的每日摘要。